ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 351,62
0,03%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) Actualités

CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DateHeureSourceTitreSymboleSociété
29/05/202414h30PR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202413h00PR Newswire (US)Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202422h05PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
10/05/202414h30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
30/04/202422h05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
26/04/202414h00PR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
11/04/202414h30PR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
04/04/202414h30PR Newswire (US)Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
18/03/202413h30PR Newswire (US)Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
07/03/202414h30PR Newswire (US)Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramNASDAQ:CTXRCitius Pharmaceuticals Inc
04/03/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTXRCitius Pharmaceuticals Inc
26/02/202413h30PR Newswire (US)Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202422h23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202422h18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202414h30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202422h30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202414h01PR Newswire (US)Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202422h15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202422h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202414h30PR Newswire (US)Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202414h31PR Newswire (US)Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage CathetersNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202414h30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
29/12/202322h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTXRCitius Pharmaceuticals Inc
09/11/202314h30PR Newswire (US)Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023NASDAQ:CTXRCitius Pharmaceuticals Inc
31/10/202313h45PR Newswire (US)Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint InhibitorNASDAQ:CTXRCitius Pharmaceuticals Inc
24/10/202313h58Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CTXRCitius Pharmaceuticals Inc
24/10/202313h30GlobeNewswire Inc.Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.NASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
BNP
BNP Paribas
NYSE
NKE
Nike
EU
GLE
Societe Generale
EU
MC
Lvmh Moet Hennessy Louis...
EU
BN
Danone
EU
VIV
Vivendi
COIN
BTCUSD
Bitcoin
EU
ORA
Orange
FTSE
UKX
FTSE 100
EU
LR
Legrand
SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
EU
CAP
Capgemini
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés